KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Capital Expenditures (2020 - 2025)

Ginkgo Bioworks Holdings filings provide 6 years of Capital Expenditures readings, the most recent being $5000.0 for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 99.96% to $5000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $7.7 million, a 87.74% decrease, with the full-year FY2025 number at $7.7 million, down 87.74% from a year prior.
  • Capital Expenditures hit $5000.0 in Q4 2025 for Ginkgo Bioworks Holdings, down from $38000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $27.0 million in Q2 2024 to a low of $5000.0 in Q4 2025.
  • Median Capital Expenditures over the past 5 years was $9.6 million (2022), compared with a mean of $11.6 million.
  • Biggest five-year swings in Capital Expenditures: surged 443.04% in 2023 and later crashed 99.96% in 2025.
  • Ginkgo Bioworks Holdings' Capital Expenditures stood at $5.1 million in 2021, then soared by 401.47% to $25.6 million in 2022, then crashed by 86.56% to $3.4 million in 2023, then surged by 297.85% to $13.7 million in 2024, then crashed by 99.96% to $5000.0 in 2025.
  • The last three reported values for Capital Expenditures were $5000.0 (Q4 2025), $38000.0 (Q2 2025), and $7.6 million (Q1 2025) per Business Quant data.